Plasma cell-free circulating tumor DNA (ctDNA) detection in longitudinally followed glioblastoma patients using <i>TERT</i> promoter mutation-specific droplet digital PCR assays.

Christine Cordova(Cleveland Clinic), Rajan Jain(NYU Langone Health), Minerva Utate(NYU Langone’s Laura and Isaac Perlmutter Cancer Center), Broderick C. Corless(Cornell University), Zacharia Sawaged(NYU Langone Health), David Zagzag(NYU Langone Health), John G. Golfinos(NYU Langone Health), Mahrukh M. Syeda(NYU Langone Health), George Karlin‐Neumann(Bio-Rad (United States)), Jessica Schafrick(NYU Langone Health), Malcolm Delara(NYU Langone Health), David Polsky(New York University), Dimitris G. Placantonakis(New York University), Sylvia C. Kurz(Center for Neuro-Oncology), Matija Snuderl, Joshua S. Silverman(NYU Langone Health), Yongzhao Shao(New York University), Jennifer Wiggins(New York University), Amie Patel(NYU Langone Health)
Journal of Clinical Oncology
May 20, 2019
Cited by 12


Related Papers